Medications for Polycythemia Vera

2 results
  • jakafi - ruxolitinib tablet

    (Ruxolitinib)
    Incyte Corporation
    Jakafi treats intermediate or high-risk myelofibrosis and polycythemia vera (in adults intolerant of or unresponsive to hydroxyurea). Also indicated for steroid-refractory acute and chronic graft-versus-host disease in adults and pediatric patients 12 and older.